James Aloysius Brady
Director · Xeris Biopharma Holdings, Inc.
- 2025
- Jun 5, 2026
- 4
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies James Aloysius Brady files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Kevin McCulloch - $1.36M in XERS purchases and sales in the last 12 months
- Beth Hecht - $1.34M in XERS purchases and sales in the last 12 months
- Steven Pieper - $515K in XERS purchases and sales in the last 12 months
- John Patrick Shannon Jr. - $173K in XERS purchases and sales in the last 12 months
- Dawn Halkuff - $122K in XERS purchases and sales in the last 12 months
- Barbara-Jean Anne Bormann-Kennedy - $98K in XERS purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is James Aloysius Brady?
James Aloysius Brady is a corporate insider, tracked as Director of Xeris Biopharma Holdings, Inc. (XERS). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did James Aloysius Brady last file a Form 4?
The most recent primary Form 4 on record is dated 5 June 2026, one of 4 filings going back to 2025.
Has James Aloysius Brady been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($71K) across all tracked filings.
